Dr. Grey AI

Etelcalcetide (Parsabiv)

Peptide

Etelcalcetide is a synthetic D-amino acid peptide calcimimetic approved for secondary hyperparathyroidism (SHPT) in hemodialysis patients. FDA-approved in 2017, it is the first IV calcimimetic. Phase III trials showed 74-75% of patients achieved >30% PTH reduction vs 8-10% placebo. Administered via IV injection at end of hemodialysis 3x/week.

Quick Answer

What it is

Etelcalcetide is a synthetic D-amino acid peptide calcimimetic approved for secondary hyperparathyroidism (SHPT) in hemodialysis patients. FDA-approved in 2017, it is the first IV calcimimetic.

Key findings

  • Grade A: PTH Reduction (Secondary Hyperparathyroidism)
  • Grade A: PTH Target Achievement (Secondary Hyperparathyroidism)
  • Grade A: Serum Calcium (Secondary Hyperparathyroidism)

Safety

  • Effective reduction in serum calcium levels, though hypocalcemia-related adverse events require monitoring and dose adjustment.
⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Etelcalcetide (Parsabiv)

Quick Facts: Etelcalcetide (Parsabiv)

  • Best Evidence:Grade A
  • Conditions Studied:1
  • Research Outcomes:9
  • Grade A Findings:4
  • Grade B Findings:3
  • Key Effect:Secondary Hyperparathyroidism
A4
B3
C1
D1
1 conditions · 9 outcomes

Detailed Outcomes

A
PTH Reduction
74-75% achieved >30% PTH reduction vs 8-10% placebo. Real-world: median PTH from 636 to 357 pg/mL. Superior to cinacalcet in head-to-head trial.
large↓Improves
A
PTH Target Achievement
Significant increase in patients achieving PTH targets (150-600 pg/mL). Responder rate increased from 27% to 63% in real-world study.
large↑Improves
A
Serum Calcium
Effective reduction in serum calcium levels, though hypocalcemia-related adverse events require monitoring and dose adjustment.
moderate↑Improves
A
Serum Phosphorus
Reduction in serum phosphorus levels observed alongside PTH reduction in clinical trials.
moderate↓Improves
B
FGF23 Levels
Secondary decrease in fibroblast growth factor-23 levels associated with improved mineral metabolism.
moderate↓Improves
B
Kidney Function
23 human trials support this finding. Human clinical trial data available.
moderate↑Improves
B
Safety/Tolerability
8 human trials support this finding. Human clinical trial data available.
moderate↑Improves
C
Cardiac Protection
3 human trials support this finding. Human clinical trial data available.
small↑Improves
D
Anti-Aging
2 human trials support this finding. Human clinical trial data available.
small↑Improves

Research Citations (43)

Adverse events reporting of Etelcalcetide: a real-word analysis from FAERS database.
(2025)
PMID: 40170738
Real-world safety profile of etelcalcetide in dialysis-related secondary hyperparathyroidism: a pharmacovigilance analysis of FAERS data.
(2025)
PMID: 40605277
The calcium-sensing receptor: a comprehensive review on its role in calcium homeostasis and therapeutic implications.
(2025)
PMID: 40226019
Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies.
(2024)
PMID: 38499495
Effects of active vitamin D analogs and calcimimetic agents on PTH and bone mineral biomarkers in hemodialysis patients with SHPT: a network meta-analysis.
(2024)
PMID: 39002024
Effect of etelcalcetide versus alfacalcidol on left ventricular function and feature-tracking cardiac magnetic resonance imaging in hemodialysis-a post-hoc analysis of a randomized, controlled trial.
(2023)
PMID: 37932788
Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
(2022)
PMID: 34273436
Cardio-renal interaction - Clinical trials update 2022.
(2022)
PMID: 36064690
Phase 1, single-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of etelcalcetide in pediatric patients with secondary hyperparathyroidism receiving hemodialysis.
(2021)
PMID: 32647975
Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan.
(2021)
PMID: 32816132